![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0094.jpg)
Anti-CTLA-4 (CD152) Ipilimumab first approved
immunoregulatory mAb
N Engl J Med. 2010 Aug 19;363(8):711-23.
Median OS 10.0 months - ipilimumab plus gp100, vs 6.4 months gp100 alone (HR
for death, 0.68; P<0.001). Median OS with ipilimumab alone was 10.1 months
.